Advancing Clinical Development in Type 1 Diabetes Through Treg Therapies That Deliver Durable Immune Tolerance

12:00 pm - Wednesday 24th March 2027

  • Reviewing emerging clinical insights from Treg therapies in Type 1 Diabetes to assess potential for durable disease modification
  • Evaluating clinical endpoints that capture immune tolerance and long-term therapeutic benefit beyond conventional disease measures
  • Addressing regulatory and development challenges to support the successful advancement of next-generation Treg therapies in autoimmune disease

Speakers:

Chief Medical Officer
GentiBio